Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Thomas C. Abshire MD

Thomas C. Abshire MD


Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology/Oncology
Program: Hematology

Research Experience

  • Blood Coagulation Disorders, Inherited
  • Clinical Trial
  • Hemostasis
  • Thrombosis
  • von Willebrand Disease
  • Clinical trials in hemostasis and thrombosis including laboratory evaluation, therapeutic intervention and new product development.
  • Evaluation of mild bleeding disorders in children including the role of the clinical history and in clinical trials in Von Willebrand Disease.
  • Clinical Expertise

  • Blood Coagulation Disorders
  • Hematologic Diseases
  • Hemorrhagic Disorders
  • Thrombosis
  • von Willebrand Disease
  • Publications

  • Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations. (Boylan B, Rice AS, De Staercke C, Eyster ME, Yaish HM, Knoll CM, Bean CJ, Miller CH, Hemophilia Inhibitor Research Study Investigators) J Thromb Haemost 2015 Jun;13(6):1036-42 PMID: 25780857 PMCID: PMC4512234
  • Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. (Holm E, Abshire TC, Bowen J, Álvarez MT, Bolton-Maggs P, Carcao M, Federici AB, Gill JC, Halimeh S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E) Blood Coagul Fibrinolysis 2015 Jun;26(4):383-8 PMID: 25688461
  • Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. (Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH, Hemophilia Inhibitor Research Study Investigators, Hemophilia Inhibitor Research Study Investigators) J Thromb Haemost 2015 Jan;13(1):47-53 PMID: 25354263 PMCID: PMC4383171
  • A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. (Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT, Haemophilia Inhibitor Research Study Investigators) Haemophilia 2014 Mar;20(2):230-7 PMID: 24261612 PMCID: PMC4519821
  • Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. (Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM, Hemophilia Inhibitor Research Study Investigators) J Thromb Haemost 2013 Jul;11(7):1300-9 PMID: 23601690 PMCID: PMC4477744
  • Evaluation for bleeding disorders in suspected child abuse. (Anderst JD, Carpenter SL, Abshire TC, Section on Hematology/Oncology and Committee on Child Abuse and Neglect of the American Academy of Pediatrics) Pediatrics 2013 Apr;131(4):e1314-22 PMID: 23530182
  • Evaluating for suspected child abuse: conditions that predispose to bleeding. (Carpenter SL, Abshire TC, Anderst JD, Section on Hematology/Oncology and Committee on Child Abuse and Neglect of the American Academy of Pediatrics) Pediatrics 2013 Apr;131(4):e1357-73 PMID: 23530171
  • No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. (Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR) Blood 2013 May 2;121(18):3742-4 PMID: 23520336 PMCID: PMC3643771
  • Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). (Abshire TC, Federici AB, Alvárez MT, Bowen J, Carcao MD, Cox Gill J, Key NS, Kouides PA, Kurnik K, Lail AE, Leebeek FW, Makris M, Mannucci PM, Winikoff R, Berntorp E, VWD PN) Haemophilia 2013 Jan;19(1):76-81 PMID: 22823000 PMCID: PMC4514514
  • Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. (Kempton CL, Abshire TC, Deveras RA, Hoots WK, Gill JC, Kessler CM, Key NS, Konkle BA, Kuriakose P, Macfarlane DE, Bergman G) Haemophilia 2012 Sep;18(5):798-804 PMID: 22512291
  • TAFI made stickier. (Abshire T) Blood 2012 Apr 12;119(15):3380-1 PMID: 22500053
  • Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. (Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM, Hemophilia Inhibitor Research Study Investigators) J Thromb Haemost 2012 Jun;10(6):1055-61 PMID: 22435927 PMCID: PMC4477703
  • VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. (Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR) Blood 2012 Mar 1;119(9):2135-40 PMID: 22197721 PMCID: PMC3311248
  • A community-based partnership to promote information infrastructure for bleeding disorders. (Aschman DJ, Abshire TC, Shapiro AD, Lusher JM, Forsberg AD, Kulkarni R) Am J Prev Med 2011 Dec;41(6 Suppl 4):S332-7 PMID: 22099355
  • F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. (Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W, Hemophilia Inhibitor Research Study Investigators) Haemophilia 2012 May;18(3):375-82 PMID: 22103590
  • The principal results of the International Immune Tolerance Study: a randomized dose comparison. (Hay CR, DiMichele DM, International Immune Tolerance Study) Blood 2012 Feb 9;119(6):1335-44 PMID: 22101900
  • Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. (Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, Manco-Johnson MJ, Monahan PE, Joint Outcome Study Investigators) Gene Ther 2012 Mar;19(3):288-94 PMID: 21697954
  • In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. (Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Cohen AJ, Key NS, Thompson AR, Abshire TC) J Thromb Haemost 2010 Oct;8(10):2224-31 PMID: 20704648 PMCID: PMC3612936
  • Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII. (Kempton CL, Meeks SL, Donald Harvey R 3rd, Abshire TC) Haemophilia 2011 Jan;17(1):155-6 PMID: 20579112
  • Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. (Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR) Blood 2010 Jul 15;116(2):280-6 PMID: 20231421 PMCID: PMC2910611
  • The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. (Goldenberg NA, Tripputi M, Crowther M, Abshire TC, DiMichele D, Manco-Johnson MJ, Hiatt WR) Contemp Clin Trials 2010 Jan;31(1):131-3 PMID: 19941974
  • Inhibitors of factor VIII in black patients with hemophilia. (Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howard TE) N Engl J Med 2009 Apr 16;360(16):1618-27 PMID: 19369668 PMCID: PMC2761028
  • Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment. (Meeks SL, Abshire TC) Haemophilia 2008 Nov;14(6):1159-63 PMID: 19141155
  • Diagnosis of type 1 VWD: can the clinical history trump laboratory findings? (Abshire TC) Pediatr Blood Cancer 2009 Jan;52(1):7-8 PMID: 19006252
  • One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. (Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Sawaf H, Loh ML, Rogers ZR, Glader BE, McCarthy MC, Mahoney DH, Olson TA, Feig SA, Lorenzana AN, Mentzer WC, Buchanan GR, Neufeld EJ, Pediatric Rituximab/ITP Study Group, Glaser Pediatric Research Network) Pediatr Blood Cancer 2009 Feb;52(2):259-62 PMID: 18937333
  • Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. (Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL) N Engl J Med 2007 Aug 9;357(6):535-44 PMID: 17687129
  • Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy. (Dunn AL, Abshire TC) Pediatr Blood Cancer 2008 Mar;50(3):627-9 PMID: 17143876
  • Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. (Kempton CL, Soucie JM, Abshire TC) J Thromb Haemost 2006 Dec;4(12):2576-81 PMID: 17002659
  • Prophylaxis and von Willebrand's disease (vWD). (Abshire TC) Thromb Res 2006;118 Suppl 1:S3-7 PMID: 16580053
  • Current issues in prophylactic therapy for persons with hemophilia. (Dunn AL, Abshire TC) Acta Haematol 2006;115(3-4):162-71 PMID: 16549891
  • Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease. (Josephson CD, Abshire TC) Best Pract Res Clin Haematol 2006;19(1):35-49 PMID: 16377540
  • Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. (Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ) Blood 2006 Apr 1;107(7):2639-42 PMID: 16352811 PMCID: PMC1895391
  • Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy. (Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC) J Thromb Haemost 2005 Jul;3(7):1541-2 PMID: 15978117
  • Recent advances in the management of the child who has hemophilia. (Dunn AL, Abshire TC) Hematol Oncol Clin North Am 2004 Dec;18(6):1249-76, viii PMID: 15511615
  • The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. (Shapiro AD, Di Paola J, Cohen A, Pasi KJ, Heisel MA, Blanchette VS, Abshire TC, Hoots WK, Lusher JM, Negrier C, Rothschild C, Roth DA) Blood 2005 Jan 15;105(2):518-25 PMID: 15383463
  • Arthroscopic synovectomy for hemophilic joint disease in a pediatric population. (Dunn AL, Busch MT, Wyly JB, Sullivan KM, Abshire TC) J Pediatr Orthop 2004 Jul-Aug;24(4):414-26 PMID: 15205625
  • IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. (Bussel JB, Eldor A, Kelton JG, Varon D, Brenner B, Gillis S, Angiolillo A, Kulkarni R, Abshire TC, Kelleher J, IGIV-C in ITP Study Group) Thromb Haemost 2004 Apr;91(4):771-8 PMID: 15045139
  • An approach to the diagnosis and treatment of bleeding disorders in infants. (Abshire TC) Int J Hematol 2002 Aug;76 Suppl 2:265-70 PMID: 12430935
  • Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. (Fried MW, Peter J, Hoots K, Gaglio PJ, Talbut D, Davis PC, Key NS, White GC, Lindblad L, Rickles FR, Abshire TC) Hepatology 2002 Oct;36(4 Pt 1):967-72 PMID: 12297845
  • Radionuclide synovectomy for hemophilic arthropathy: a comprehensive review of safety and efficacy and recommendation for a standardized treatment protocol. (Dunn AL, Busch MT, Wyly JB, Abshire TC) Thromb Haemost 2002 Mar;87(3):383-93 PMID: 11916068
  • Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. (Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR) Blood 2000 Sep 1;96(5):1709-15 PMID: 10961868
  • Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. (Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E) Thromb Haemost 2000 Jun;83(6):811-6 PMID: 10896230
  • Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. (Zhou M, Gu L, Abshire TC, Homans A, Billett AL, Yeager AM, Findley HW) Leukemia 2000 Jan;14(1):61-7 PMID: 10637478
  • Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. (Tomer A, Masalunga C, Abshire TC) Am J Hematol 1999 May;61(1):53-61 PMID: 10331512
  • Coagulopathy in pediatric abusive head trauma. (Hymel KP, Abshire TC, Luckey DW, Jenny C) Pediatrics 1997 Mar;99(3):371-5 PMID: 9041291
  • Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study. (Bernstein ML, Abshire TC, Pollock BH, Devine S, Toledano S, Steuber CP, Bowman WP, Buchanan GR) J Pediatr Hematol Oncol 1997 Jan-Feb;19(1):68-72 PMID: 9065722
  • The prolonged thrombin time of nephrotic syndrome. (Abshire TC, Fink LK, Christian J, Hathaway WE) J Pediatr Hematol Oncol 1995 May;17(2):156-62 PMID: 7749766
  • Prevalence of von Willebrand disease in children: a multiethnic study. (Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC) J Pediatr 1993 Dec;123(6):893-8 PMID: 8229521
  • Dysfunctional protein C deficiency (type II). A report of 11 cases in 3 American families and review of the literature. (Berdeaux DH, Abshire TC, Marlar RA) Am J Clin Pathol 1993 Jun;99(6):677-86 PMID: 8322701
  • Philadelphia chromosome-positive chronic myeloid leukemia and thoracic ganglioneuroma. Previously undescribed association. (Shea MP, Abshire TC) Am J Pediatr Hematol Oncol 1993 Feb;15(1):111-4 PMID: 8447551
  • Relative value of diagnostic studies for von Willebrand disease. (Werner EJ, Abshire TC, Giroux DS, Tucker EL, Broxson EH) J Pediatr 1992 Jul;121(1):34-8 PMID: 1625090
  • Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. (Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D, Behm F, Crist WM, Link M, Borowitz M) Leukemia 1992 May;6(5):357-62 PMID: 1534389
  • Molecular genetic studies in black families with sickle cell anemia and unusually high levels of fetal hemoglobin. (Seltzer WK, Abshire TC, Lane PA, Roloff JS, Githens JH) Hemoglobin 1992;16(5):363-77 PMID: 1385360
  • Severe neonatal protein C deficiency: prevalence and thrombotic risk. (Manco-Johnson MJ, Abshire TC, Jacobson LJ, Marlar RA) J Pediatr 1991 Nov;119(5):793-8 PMID: 1834822
  • The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis? (Abshire TC, Gold SH, Odom LF, Carson SD, Hathaway WE) Cancer 1990 Aug 15;66(4):716-21 PMID: 2386901
  • Zinc status in children and young adults with sickle cell disease. (Abshire TC, English JL, Githens JH, Hambidge M) Am J Dis Child 1988 Dec;142(12):1356-9 PMID: 3195534
  • Anemia of acute inflammation in children. (Abshire TC, Reeves JD) J Pediatr 1983 Dec;103(6):868-71 PMID: 6644420
  • Last update: 06/04/2015